Blarcamesine potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancementImpairment of autophagy ...

Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

The finding has implications for all of us, write Harvard physician-researchers Christopher Worsham and Anupam Jena.

New expensive but disease-modifying treatments are expected to foster Alzheimer’s disease market growth globally, according ...

Treatment with an oral allosteric modulator was nonsuperior to placebo at 6 weeks in adults with Parkinson’s disease whose ...

Dementia cases in the U.S. are expected to double by 2060, with an estimated one million people diagnosed per year, according ...

The headset, developed by researchers at Cornell University in New York, could help reveal how the brain navigates and ...

Beckman Coulter Diagnostics, a global leader in advanced diagnostics, today announced availability of new Research Use Only ...

Expanded clinical practice guidelines aim to empower all clinicians, regardless of specialty or practice setting to evaluate ...

Mizuho Securities analyst Anthony Petrone has maintained their bullish stance on LNTH stock, giving a Buy rating yesterday.Stay Ahead of the ...

Discover how a groundbreaking cognitive assessment tool is transforming early dementia detection with 99.9% accuracy and what this means for future treatment.

The agency expects to issue a decision by Aug. 31, and it is slated to decide on maintenance dosing for an intravenous form of the drug later this month.